Sugi Predict

Sugi Predict / Compounds / SCHEMBL11968637

SCHEMBL11968637

SCHEMBL11968637

CCc1ccccc1-c1c[nH]c2ncc(-c3cncc(C(O)C(=O)N(C)C)c3)cc12

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 3/20 0.53
▸ SGK1 O00141 5/20 0.50
▸ CAMKK2 Q96RR4 3/20 0.50
▸ MAP4K1 Q92918 3/20 0.47
▸ CYP3A4 P08684 2/20 0.47
▸ CCNT1 O60563 1/20 0.46
▸ CCNA2 P20248 1/20 0.46
▸ CDK2 P24941 1/20 0.46
▸ CDK9 P50750 1/20 0.46
▸ MAP3K11 Q16584 1/20 0.43
▸ PLCG1 P19174 2/20 0.42
▸ PDPK1 O15530 2/20 0.42
▸ AXL P30530 4/20 0.41
▸ NEK1 Q96PY6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11968677 0.89 ABL1 (0.55) ABL1SGK1CAMKK2MAP4K1MAP3K11
SCHEMBL11968636 0.88 ABL1 (0.54) ABL1SGK1CAMKK2MAP4K1MAP3K11
SCHEMBL11968641 0.88 ABL1 (0.54) ABL1SGK1CAMKK2MAP4K1MAP3K11
SCHEMBL11968623 0.88 SGK1 (0.56) ABL1SGK1CAMKK2CDK2MAP3K11
SCHEMBL11968624 0.87 ABL1 (0.53) ABL1SGK1CAMKK2MAP4K1MAP3K11
SCHEMBL5060932 0.86 ABL1 (0.72) ABL1SGK1CAMKK2MAP4K1MAP3K11
SCHEMBL11968640 0.86 ABL1 (0.52) ABL1SGK1CAMKK2MAP4K1CCNT1
SCHEMBL11968543 0.86 ABL1 (0.72) ABL1SGK1CAMKK2MAP4K1MAP3K11
SCHEMBL4374487 0.86 ABL1 (0.72) ABL1SGK1CAMKK2MAP4K1MAP3K11
SCHEMBL11968613 0.85 NEK1 (0.58) ABL1SGK1CCNT1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242280-B2 morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia SGX PHARMACEUTICALS, INC. (US) 2012-08-14 — — US disclosed
US-8242280-B2 morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia SGX PHARMACEUTICALS, INC. (US) 2012-08-14 — — US disclosed
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed
WO-2008124848-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS MAP3K20, MAP3K19, MAP4K2 ABL1 110/4885SGK1 323/4885CAMKK2 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.